MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
0.8800
-0.0200
-2.22%
Pre Market: 0.8976 +0.0176 +2.00% 08:32 05/14 EDT
OPEN
0.9201
PREV CLOSE
0.9000
HIGH
0.9507
LOW
0.8600
VOLUME
49
TURNOVER
0
52 WEEK HIGH
2.220
52 WEEK LOW
0.5480
MARKET CAP
10.90M
P/E (TTM)
-0.4567
1D
5D
1M
3M
1Y
5Y
1D
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 5h ago
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6
Benzinga · 5h ago
Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year
TipRanks · 1d ago
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress
TipRanks · 1d ago
Aprea Therapeutics GAAP EPS of -$0.22 beats by $0.01
Seeking Alpha · 1d ago
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall
Reuters · 1d ago
Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate
Benzinga · 1d ago
Aprea Therapeutics Q1 FY26 net loss narrows to $3.3 million
PUBT · 1d ago
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.